Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
43 hedge funds and large institutions have $32.8M invested in Kezar Life Sciences in 2026 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 10 closing their positions.
62% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $784K
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
17% more capital invested
Capital invested by funds: $28.1M → $32.8M (+$4.79M)
0% more funds holding
Funds holding: 43 → 43 (0)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$1.02M |
| 2 |
Millennium Management
New York
|
+$924K |
| 3 |
GLF
Groupe la Francaise
Paris,
France
|
+$523K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$386K |
| 5 |
Renaissance Technologies
New York
|
+$372K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.74M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$982K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$333K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$325K |
| 5 |
FIA
FNY Investment Advisers
New York
|
-$314K |
KZR Hedge Fund Activity: Q1 2026 in Review
43 of the 8,161 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2026, worth a combined $32.8M — up 17% from $28.1M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new KZR positions and 10 closed out — a net gain of 3 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Rangeley Capital, adding an estimated $1.02M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.74M sold.
- 43 institutional investors held Kezar Life Sciences (KZR) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $32.8M of Kezar Life Sciences stock for Q1 2026, up 17% quarter-over-quarter.
- 13 funds opened new Kezar Life Sciences positions in Q1 2026 and 10 closed out, a net change of +3 holders.
- The largest Kezar Life Sciences buyer in Q1 2026 was Rangeley Capital, an estimated $1.02M added.
- The largest Kezar Life Sciences seller in Q1 2026 was Nantahala Capital Management, an estimated $1.74M sold.
Based on aggregated 13F filings for Q1 2026.